Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-4rdrl Total loading time: 0 Render date: 2024-06-21T02:11:09.707Z Has data issue: false hasContentIssue false

Chapter 29 - Luteal Phase Support Other than Progesterone

from Section 6 - Procedures before, during, and after Ovarian Stimulation

Published online by Cambridge University Press:  14 April 2022

By
Dalia Khalife ,
Nour Assaf  and
Johnny Awwad
Edited by
Mohamed Aboulghar  and
Botros Rizk
Mohamed Aboulghar
Affiliation:
University of Cairo IVF Centre
Botros Rizk
Affiliation:
University of South Alabama
Get access

Summary

Deficiencies in luteal hormonal dynamics have been clearly documented during controlled ovarian stimulation [1]. Disruptions to the physiological secretion of luteinizing hormone (LH) by the anterior pituitary affect optimal corpus luteum (CL) function warranting some form of luteal phase support (LPS) in order to maintain optimal endometrial receptivity in stimulated cycles.

Type
Chapter
Information
Ovarian Stimulation , pp. 302 - 310
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Edwards, RG, Steptoe, PC, Purdy, JM. Establishing full‐term human pregnancies using cleaving embryos grown in vitro. BJOG 1980;87(9):737–756.CrossRefGoogle ScholarPubMed
Gardner, DK, Weissman, A, Howles, CM, Shoham, Z (eds.). Textbook of Assisted Reproductive Techniques: Laboratory and Clinical Perspectives. Boca Raton: CRC Press; 2016.Google Scholar
Messinis, IE, Messini, CI, Dafopoulos, K. Luteal-phase endocrinology. Reprod Biomed Online 2009;19:15–29.Google Scholar
Pabuccu, R, Akar, ME. Luteal phase support in assisted reproductive technology. Curr Opin Obstet Gynecol 2005;17(3):277–281.CrossRefGoogle ScholarPubMed
De Ziegler, D, Cedars, MI, Randle, D, et al. Suppression of the ovary using a gonadotropin releasing-hormone agonist prior to stimulation for oocyte retrieval. Fertil Steril 1987;48(5):807–810.Google Scholar
Neveu, S, Hedon, B, Bringer, J, et al. Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization. Fertil Steril 1987;47(4):639–643.Google Scholar
Fraser, HM. Effect of oestrogen on gonadotrophin release in stumptailed monkeys (Macaca arctoides) treated chronically with an agonist analogue of luteinizing hormone releasing hormone. J Endocrinol 1981;91(3):525–530.Google Scholar
Fauser, BC, Devroey, P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab 2003;14(5):236–242.Google Scholar
Miyake, A, Aono, T, Kinugasa, T, Tanizawa, O, Kurachi, K. Suppression of serum levels of luteinizing hormone by short- and long-loop negative feedback in ovariectomized women. J Endocrinol 1979;80(3):353–356.CrossRefGoogle Scholar
Smitz, J, Devroey, P, Van Steirteghem, AC. Endocrinology in luteal phase and implantation. Br Med Bull 1990;46(3):709–719.Google Scholar
Messinis, IE, Bergh, T, Wide, L. The importance of human chorionic gonadotropin support of the corpus luteum during human gonadotropin therapy in women with anovulatory infertility. Fertil Steril 1988;50(1):31–35.CrossRefGoogle ScholarPubMed
Belaisch-Allart, J, De Mouzon, J, Lapousterle, C, Mayer, M. The effect of HCG supplementation after combined GnRH agonist/HMG treatment in an IVF programme. Hum Reprod 1990;5(2):163–166.CrossRefGoogle Scholar
Kupferminc, MJ, Lessing, JB, Amit, A, et al. A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in-vitro fertilization and embryo transfer. Hum Reprod 1990;5(3):271–273.Google Scholar
Beckers, NG, Laven, JS, Eijkemans, MJ, Fauser, BC. Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization. Hum Reprod 2000;15(1):43–49.Google Scholar
van der Linden, M, Buckingham, K, Farquhar, C, Kremer, JA, Metwally, M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2015;7:CD009154.Google Scholar
Humaidan, P, Ejdrup Bredkjaer, H, Bungum, L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005;20(5):1213–1220.Google Scholar
Shapiro, BS, Daneshmand, ST, Garner, FC, Aguirre, M, Hudson, C. Comparison of “triggers” using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Fertil Steril 2011;95(8):2715–2717.Google Scholar
Engmann, L, Romak, J, Nulsen, J, Benadiva, C, Peluso, J. In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation. Fertil Steril 2011;96(1):198–202.CrossRefGoogle ScholarPubMed
Shapiro, BS, Daneshmand, ST, Garner, FC, Aguirre, M, Thomas, S. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization. Fertil Steril 2008;90(1):231–233.CrossRefGoogle ScholarPubMed
Humaidan, P, Bredkjær, HE, Westergaard, LG, Andersen, CY. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010;93(3):847–854.Google Scholar
Humaidan, P. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reprod Biomed Online 2009;18(5):630–634.Google Scholar
Humaidan, P, Bungum, L, Bungum, M, Andersen, CY. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online 2006;13(2):173–178.Google Scholar
Seyhan, A, Ata, B, Polat, M, et al. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod 2013;28(9):2522–2528.Google Scholar
Andersen, CY, Fischer, R, Giorgione, V, Kelsey, TW. Micro-dose hCG as luteal phase support without exogenous progesterone administration: mathematical modelling of the hCG concentration in circulation and initial clinical experience. J Assist Reprod Genet 2016;33(10):1311–1318.Google Scholar
Humaidan, P, Polyzos, NP, Alsbjerg, B, et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod 2013;28(9):2511–2521.Google Scholar
Andersen, CY, Andersen, KV. Improving the luteal phase after ovarian stimulation: reviewing new options. Reprod Biomed Online 2014;28(5):552–559.Google Scholar
Thuesen, LL, Loft, A, Egeberg, AN, et al. A randomized controlled dose–response pilot study of addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization. Hum Reprod 2012;27(10):3074–3084.Google Scholar
De Ziegler, D, Pirtea, P, Andersen, CY, Ayoubi, JM. Role of gonadotropin-releasing hormone agonists, human chorionic gonadotropin (hCG), progesterone, and estrogen in luteal phase support after hCG triggering, and when in pregnancy hormonal support can be stopped. Fertil Steril 2018;109(5):749–755.CrossRefGoogle ScholarPubMed
Papanikolaou, EG, Verpoest, W, Fatemi, H, et al. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertil Steril 2011;95(3):1174–1177.CrossRefGoogle ScholarPubMed
Kang, IS, Kuehl, TJ, Siler-Khodr, TM. Effect of treatment with gonadotropin-releasing hormone analogues on pregnancy outcome in the baboon. Fertil Steril 1989;52(5):846–853.Google Scholar
Skarin, G, Nillius, SJ, Wide, L. Failure to induce early abortion by huge doses of a superactive LRH agonist in women. Contraception 1982;26(5):457–463.CrossRefGoogle ScholarPubMed
Bar Hava, I, Blueshtein, M, Herman, HG, Omer, Y, David, GB. Gonadotropin-releasing hormone analogue as sole luteal support in antagonist-based assisted reproductive technology cycles. Fertil Steril 2017;107(1):130–135.Google Scholar
Tesarik, J, Hazout, A, Mendoza, C. Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Hum Reprod 2004;19(5):1176–1180.Google Scholar
Pirard, C, Loumaye, E, Laurent, P, Wyns, C. Contribution to more patient-friendly ART treatment: efficacy of continuous low-dose GnRH agonist as the only luteal support – results of a prospective, randomized, comparative study. Int J Endocrinol 2015;2015:727569.Google Scholar
Pirard, C, Donnez, J, Loumaye, E. GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin. Hum Reprod 2005;20(7):1798–1804.Google Scholar
Tesarik, J, Hazout, A, Mendoza-Tesarik, R, Mendoza, N, Mendoza, C. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod 2006;21(10):2572–2579.CrossRefGoogle ScholarPubMed
Yıldız, GA, Şükür, YE, Ateş, C, Aytaç, R. The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 2014;182:66–70.Google Scholar
Aboulghar, MA, Marie, H, Amin, YM, et al. GnRH agonist plus vaginal progesterone for luteal phase support in ICSI cycles: a randomized study. Reprod Biomed Online 2015;30(1):52–56.Google Scholar
Pirard, C, Donnez, J, Loumaye, E. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod 2006;21(7):1894–1900.Google Scholar
Kawamura, K, Fukuda, J, Kumagai, J, et al. Gonadotropin-releasing hormone I analog acts as an antiapoptotic factor in mouse blastocysts. Endocrinology 2005;146(9):4105–4116.Google Scholar
Wong, KH, Simon, JA. In vitro effect of gonadotropin-releasing hormone agonist on natural killer cell cytolysis in women with and without endometriosis. Am J Obstet Gynecol 2004;190(1):44–49.Google Scholar
Kyrou, D, Kolibianakis, EM, Fatemi, HM, et al. Increased live birth rates with GnRH agonist addition for luteal support in ICSI/IVF cycles: a systematic review and meta-analysis. Hum Reprod Update 2011;17(6):734–740.Google Scholar
Martins, WP, Ferriani, RA, Navarro, PA, Nastri, CO. GnRH agonist during luteal phase in women undergoing assisted reproductive techniques: systematic review and meta‐analysis of randomized controlled trials. Ultrasound Obstet Gynecol 2016;47(2):144–151.Google Scholar
Bhurke, AS, Bagchi, IC, Bagchi, MK. Progesterone‐regulated endometrial factors controlling implantation. Am J Reprod Immunol 2016;75(3):237–245.Google Scholar
Li, S, Li, Y. Administration of a GnRH agonist during the luteal phase frozen–thawed embryo transfer cycles: a meta-analysis. Gynecol Endocrinol 2018 ;34(11):920–924.Google Scholar
Janssens, RMJ, Brus, L, Cahill, DJ, et al. Direct ovarian effects and safety of GnRH agonists and antagonists. Hum Reprod Update 2000;6(5):505–518.Google Scholar
Cahill, DJ. The risks of GnRH agonist administration in early pregnancy. In: Filicori, M, Flamigni, C, eds. Ovulation Induction Update’98. London: Parthenon; 1998:97–106.Google Scholar
Marcus, SF, Ledger, WL. Efficacy and safety of long-acting GnRH agonists in in vitro fertilization and embryo transfer. Hum Fertil 2001;4(2):85–93.Google Scholar
Oliveira, JB, Baruffi, R, Petersen, CG, et al. Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis. Reprod Biol Endocrinol 2010;8(1):107.Google Scholar
Zhou, W, Zhuang, Y, Pan, Y, Xia, F. Effects and safety of GnRH-a as a luteal support in women undertaking assisted reproductive technology procedures: follow-up results for pregnancy, delivery, and neonates. Arch Gynecol Obstet 2017;295(5):1269–1275.Google Scholar
Orvieto, R, Kerner, R, Krissi, H, et al. Comparison of leuprolide acetate and triptorelin in assisted reproductive technology cycles: a prospective, randomized study. Fertil Steril 2002;78(6):1268–1271.Google Scholar
Bar-Hava, I, Mizrachi, Y, Karfunkel-Doron, D, et al. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders. Fertil Steril 2016;106(2):330–333.Google Scholar
Laufer, N, Navot, D, Schenker, JG. The pattern of luteal phase plasma progesterone and estradiol in fertile cycles. Am J Obstet Gynecol 1982;143(7):808–813.Google Scholar
Lipson, SF, Ellison, PT. Comparison of salivary steroid profiles in naturally occurring conception and non-conception cycles. Hum Reprod 1996;11(10):2090–2096.Google Scholar
Bouchard, P. Understanding endometrial physiology and menstrual disorders in the 1990s. Curr Opin Obstet Gynecol 1993;5(3):378–388.Google Scholar
Smitz, J, Devroey, P, Braeckmans, P, et al. Management of failed cycles in an IVF/GIFT programme with the combination of GnRH analogue and HMG. Hum Reprod 1987;2(4):309–314.Google Scholar
Hancke, K, More, S, Kreienberg, R, Weiss, JM. Patients undergoing frozen-thawed embryo transfer have similar live birth rates in spontaneous and artificial cycles. J Assist Reprod Genet 2012;29(5):403–407.Google Scholar
Fritz, MA, Westfahl, PK, Graham, RL. The effect of luteal phase estrogen antagonism on endometrial development and luteal function in women. J Clin Endocrinol Metab 1987;65(5):1006–1013.Google Scholar
Vlahos, NF, Lipari, CW, Bankowski, B, et al. Effect of luteal-phase support on endometrial L-selectin ligand expression after recombinant follicle-stimulating hormone and ganirelix acetate for in vitro fertilization. J Clin Endocrinol Metab 2006;91(10):4043–4049.CrossRefGoogle ScholarPubMed
Ghosh, D, De, P, Sengupta, J. Luteal phase ovarian oestrogen is not essential for implantation and maintenance of pregnancy from surrogate embryo transfer in the rhesus monkey. Hum Reprod 1994;9(4):629–637.Google Scholar
Farhi, J, Weissman, A, Steinfeld, Z, et al. Estradiol supplementation during the luteal phase may improve the pregnancy rate in patients undergoing in vitro fertilization-embryo transfer cycles. Fertil Steril 2000;73(4):761–766.Google Scholar
Lukaszuk, K, Liss, J, Lukaszuk, M, Maj, B. Optimization of estradiol supplementation during the luteal phase improves the pregnancy rate in women undergoing in vitro fertilization–embryo transfer cycles. Fertil Steril 2005;83(5):1372–1376.CrossRefGoogle ScholarPubMed
Ghanem, ME, Sadek, EE, Elboghdady, LA, et al. The effect of luteal phase support protocol on cycle outcome and luteal phase hormone profile in long agonist protocol intracytoplasmic sperm injection cycles: a randomized clinical trial. Fertil Steril 2009;92(2):486–493.Google Scholar
Elgindy, EA, El-Haieg, DO, Mostafa, MI, Shafiek, M. Does luteal estradiol supplementation have a role in long agonist cycles? Fertil Steril 2010;93(7):2182–2188.Google Scholar
Var, T, Tonguc, EA, Doğanay, M, et al. A comparison of the effects of three different luteal phase support protocols on in vitro fertilization outcomes: a randomized clinical trial. Fertil Steril 2011;95(3):985–989.Google Scholar
Fatemi, HM, Kolibianakis, EM, Camus, M, et al. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial. Hum Reprod 2006;21(10):2628–2632.Google Scholar
Ceyhan, ST, Basaran, M, Duru, NK, et al. Use of luteal estrogen supplementation in normal responder patients treated with fixed multidose GnRH antagonist: a prospective randomized controlled study. Fertil Steril 2008;89(6):1827–1830.Google Scholar
Kolibianakis, EM, Venetis, CA, Papanikolaou, EG, et al. Estrogen addition to progesterone for luteal phase support in cycles stimulated with GnRH analogues and gonadotrophins for IVF: a systematic review and meta-analysis. Hum Reprod 2008;23(6):1346–1354.Google Scholar
Huang, N, Situ, B, Chen, X, et al. Meta-analysis of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril 2015;103(2):367–373.Google Scholar
Pritts, EA, Atwood, AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod 2002;17(9):2287–2299.Google Scholar
Gelbaya, TA, Kyrgiou, M, Tsoumpou, I, Nardo, LG. The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis. Fertil Steril 2008;90(6):2116–2125.Google Scholar
Jee, BC, Suh, CS, Kim, SH, Kim, YB, Moon, SY. Effects of estradiol supplementation during the luteal phase of in vitro fertilization cycles: a meta-analysis. Fertil Steril 2010;93(2):428–436.Google Scholar
Wright, KP, Guibert, J, Weitzen, S, et al. Artificial versus stimulated cycles for endometrial preparation prior to frozen–thawed embryo transfer. Reprod Biomed Online 2006;13(3):321–325.CrossRefGoogle ScholarPubMed
Smitz, J, Bourgain, C, Van Waesberghe, L, et al. A prospective randomized study on oestradiol valerate supplementation in addition to intravaginal micronized progesterone in buserelin and HMG induced superovulation. Hum Reprod 1993;8(1):40–45.Google Scholar
Fanchin, R, Righini, C, Schönauer, LM, et al. Vaginal versus oral E2 administration: effects on endometrial thickness, uterine perfusion, and contractility. Fertil Steril 2001;76(5):994–998.Google Scholar
Engmann, L, DiLuigi, A, Schmidt, D, et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008;89(1):84–91.Google Scholar
Imbar, T, Kol, S, Lossos, F, et al. Reproductive outcome of fresh or frozen–thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support. Hum Reprod 2012;27(3):753–759.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×